



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

FEB 27 2013

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,291,523. The application was filed on April 27, 2011, under 35 U.S.C. § 156. Please note that patent term extension applications for U.S. Patent No. 7,115,662 for NADA 141-320 for the animal drug product ONSIOR® (robenacoxib) were filed concurrently, pursuant to the provisions of 37 C.F.R. § 1.785.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to Ali Salimi at (571) 272-0909 (telephone) or (571) 273-0909 (facsimile) or by e-mail at [ali.salimi@uspto.gov](mailto:ali.salimi@uspto.gov).

Mary C. Tilly  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Associate Commissioner  
for Patent Examination Policy

cc: Leslie Fisher  
Novartis Pharmaceutical Corporation  
One Health Plaza Bldg 104  
East Hanover, NJ 07936

RE: ONSIOR® (robenacoxib)  
Docket No. FDA-2011-E-0677